Skip to main navigation
Harrow Health

> Main Menu

About Our Company Our History Corporate Values Leadership Team Mission Work Corporate Transparency
Careers
Contact
Investors Overview News Events Letters to Stockholders Corporate Transparency Report Corporate Governance SEC Filings & Financials Stock Information Investor Resources

> Main Menu

About
Our Company Our History Corporate Values Leadership Team Mission Work Corporate Transparency
Careers Contact
Investors
Overview News Events Letters to Stockholders Corporate Transparency Report Corporate Governance SEC Filings & Financials Stock Information Investor Resources

Press Releases

November 29, 2023
Harrow Completes Transfer of the TRIESENCE® New Drug Application
November 20, 2023
Harrow to Present at Two Investor Conferences in November
November 13, 2023
Harrow Announces Third Quarter 2023 Financial Results
October 30, 2023
Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023
October 24, 2023
Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.
September 29, 2023
Harrow Health, Inc. Changes Corporate Name to Harrow, Inc.
September 26, 2023
Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation
August 9, 2023
Harrow Announces Second Quarter 2023 Financial Results
July 31, 2023
Harrow Launches VIGAMOX® in the U.S.
July 26, 2023
Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 29
Harrow Health

Address

102 Woodmont Blvd., Suite 610
Nashville, TN 37205

Phone

(615) 733 4730
(615) 733 4737 (Investor Relations)

Social

LinkedIn

Copyright © 2023 Harrow, Inc. All rights reserved.

> Footer

Privacy Policy Terms of Use Cookie Notice